Nancy Miller-Rich
CIK: 0001735084
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Jun 17, 2026FDMT
4D Molecular Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
50K shares- - Jun 9, 2026ALDX
Aldeyra Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
3.3K shares- - Jun 9, 2026ALDX
Aldeyra Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
70K shares- - Jun 17, 2025FDMT
4D Molecular Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
22.5K shares- - Jun 10, 2025ALDX
Aldeyra Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
2.4K shares- - Jun 10, 2025ALDX
Aldeyra Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
62.7K shares- - Apr 12, 2023ALDX
Aldeyra Therapeutics, Inc.
Purchase(P)Direct509 shares at avg. $10.13$5K - May 3, 2021ALDX
Aldeyra Therapeutics, Inc.
Purchase(P)Direct413 shares at avg. $12.81$5K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  FDMT 4D Molecular Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 50,000 | - | - | Direct |
| Jun 9, 2026 |  ALDX Aldeyra Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 3,318 | - | - | Direct |
| Jun 9, 2026 | ALDX Aldeyra Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 70,000 | - | - | Direct |
| Jun 17, 2025 | FDMT 4D Molecular Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 22,500 | - | - | Direct |
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 2,413 | - | - | Direct |
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 62,728 | - | - | Direct |
| Apr 12, 2023 | ALDX Aldeyra Therapeutics, Inc. | Purchase(P) | 509 | $10.13 | $5,156 | Direct |
| May 3, 2021 | ALDX Aldeyra Therapeutics, Inc. | Purchase(P) | 413 | $12.81 | $5,291 | Direct |
1-8 of 8 transactions
About Miller-Rich Nancy
Miller-Rich Nancy (SEC CIK 0001735084) files insider reports with the SEC as Director of 4D Molecular Therapeutics, Inc. (FDMT) and Director of Aldeyra Therapeutics, Inc. (ALDX).
Signal8 holds 5 ownership filings by Miller-Rich Nancy, all Form 4s, filed between Oct 21, 2024 and Jun 18, 2026. Those filings report 8 transactions, from May 3, 2021 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Miller-Rich Nancy's filings is in LEXINGTON, MA.
Recent filings by Miller-Rich Nancy
- Jun 17, 2026: Grant or award of FDMT derivative securities (Form 4, code A).
- Jun 9, 2026: Grants or awards of ALDX derivative securities (2 lines, Form 4, code A).
- Jun 17, 2025: Grant or award of FDMT derivative securities (Form 4, code A).
- Jun 10, 2025: Grants or awards of ALDX derivative securities (2 lines, Form 4, code A).
- Apr 12, 2023: Open-market purchase of ALDX shares (Form 4, code P).
Other insiders filing for 4D Molecular Therapeutics, Inc. (FDMT)
- Bizily Scott, Chief Legal Officer
- Kirn David
- Tomasello Shawn, Director
- THEUER CHARLES, Director
- GRAY SUSANNAH, Director
- MILLIGAN JOHN F, Director